vaccination

Potential benefits of delaying the second mRNA COVID-19 vaccine dose

Vaccination against COVID-19 with the recently approved mRNA vaccines BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) is currently underway in a large number of countries. However, high incidence rates and rapidly spreading SARS-CoV-2 variants are …

Preprint out: Potential benefits of delaying the second mRNA COVID-19 vaccine dose

We are happy that our preprint Potential benefits of delaying the second mRNA COVID-19 vaccine dose is out and available on arxiv.org. This has been a very constructive and effective collaborative effort, lead by our Ben Maier, who did all the heavy lifting, and valuable contributions by the teams of Cornelia Betsch, Michael Meyer-Hermann and by Karl Lauterbach.

VacMap

VacMap is an interactive visualization of the vaccination status in Germany. VacMap conveys a qualitative and quantitative representation of the vaccination coverage at the regional resolution.

Molecular surveillance of measles and rubella in the WHO European Region: new challenges in the elimination phase

The WHO European Region (EUR) has adopted the goal of eliminating measles and rubella but individual countries perform differently in achieving this goal. Measles virus spread across the EUR by mobile groups has recently led to large outbreaks in the …

Public health: This message must be herd

Immunization against vaccine-preventable diseases not only protects the individual but also has a social benefit. A study now shows that communicating this effect, known as herd immunity, can have a substantial impact on a person's inclination to …